1.45

8.21% 0.11

After Hours: 1.40 -0.05 -3.45%

Inmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

Inmune Bio Inc stock is traded at $1.45, with a volume of 405.92K. It is up +8.21% in the last 24 hours and up +13.28% over the past month. INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Previous Close:

$1.34

Open:

$1.35

24h Volume:

405.92K

Relative Volume:

0.96

Market Cap:

$38.55M

Revenue:

$50,000

Net Income/Loss:

$-45.93M

P/E Ratio:

-0.7536

EPS:

-1.9241

Net Cash Flow:

$-23.62M

1W Performance:

+22.88%

1M Performance:

+13.28%

6M Performance:

-21.62%

1Y Performance:

-80.19%

1-Day Range:

$1.35

$1.46

1-Week Range:

$1.17

$1.46

52-Week Range:

$1.09

$11.64

Inmune Bio Inc Stock (INMB) Company Profile

Name

Inmune Bio Inc

Sector

Healthcare (1116)

Industry

Biotechnology (622)

Phone

(858) 964-3720

Address

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2026-05-14

Latest SEC Filings

INMB's Discussions on Twitter

Compare INMB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INMB Inmune Bio Inc	1.45	38.55M	50,000	-45.93M	-23.62M	-1.9241
VRTX Vertex Pharmaceuticals Inc	441.20	112.22B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	750.57	79.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	849.04	52.80B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	309.66	41.32B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	323.87	35.95B	5.36B	287.73M	924.18M	2.5229

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Oct-21-24	Initiated	Alliance Global Partners	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Scotiabank	Sector Outperform
Jun-01-23	Initiated	Robert W. Baird	Outperform
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

Inmune Bio Inc Stock (INMB) Latest News

Apr 16, 2026

INMB Unveils Promising Preclinical Data for INB03 at Upcoming AA - GuruFocus

Apr 16, 2026

INmune Bio presents preclinical data on INB03 at AACR meeting By Investing.com - Investing.com Australia

Apr 16, 2026

Inmune Bio Inc stock (US45764T1060): Why does its innate immune focus matter more now for biotech in - AD HOC NEWS

Apr 16, 2026

INmune Bio presents preclinical data on INB03 at AACR meeting - Investing.com

Apr 16, 2026

INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models - The Manila Times

Apr 16, 2026

Breast cancer models show INmune Bio drug cut brain metastases - Stock Titan

Apr 16, 2026

Apr 14, 2026

INMune Bio, Inc. (NASDAQ:INMB) Q4 2025 earnings call transcript - MSN

Apr 14, 2026

Apr 13, 2026

Options Flow: Does INmune Bio Inc have a competitive edge2026 Macro Impact & Real-Time Chart Breakout Alerts - baoquankhu1.vn

Apr 13, 2026

Aug Highlights: What is the earnings history of INmune Bio IncBond Market & Community Consensus Stock Picks - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Lucid Capital Markets upgrades INmune Bio (INMB) - MSN

Apr 11, 2026

Apr 09, 2026

Analysis Recap: Whats the RSI of INmune Bio Inc stock2026 Trade Ideas & Daily Chart Pattern Signal Reports - baoquankhu1.vn

Apr 09, 2026

Inmune Bio Inc stock: What investors need to know about its biotech potential now - AD HOC NEWS

Apr 09, 2026

Apr 07, 2026

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - ADVFN

Apr 07, 2026

Apr 06, 2026

INmune Bio (INMB) price target increased by 33.33% to 7.14 - MSN

Apr 06, 2026

Apr 05, 2026

Support Test: Whats the RSI of INmune Bio Inc stockWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

INMB.O PE Ratio & Valuation, Is INMB.O Overvalued - Intellectia AI

Apr 04, 2026

Apr 01, 2026

INmune Bio, Inc. (NASDAQ:INMB) Q4 2025 Earnings Call Transcript - Insider Monkey

Apr 01, 2026

INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely - Yahoo Finance

Apr 01, 2026

Inmune Bio Earnings Call Balances Progress and Risk - The Globe and Mail

Apr 01, 2026

Mar 31, 2026

S P Trends: Whats the profit margin of INmune Bio IncWeekly Trade Report & Weekly Stock Performance Updates - baoquankhu1.vn

Mar 31, 2026

INmune Bio, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 31, 2026

Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference - Moomoo

Mar 31, 2026

Inmune Bio Inc Stock: Recent 2025 Results Highlight Late-Stage Pipeline Progress Amid Cash Runway to - AD HOC NEWS

Mar 31, 2026

INmune Bio reports $45.9M loss, plans UK regulatory filing By Investing.com - Investing.com South Africa

Mar 31, 2026